Cargando…
Resurrection of Oral Arsenic Trioxide for Treating Acute Promyelocytic Leukaemia: A Historical Account From Bedside to Bench to Bedside
Various forms of arsenic were used in China and elsewhere for over 5,000 years. Following the initial success of intravenous arsenic trioxide (i.v. As(2)O(3)), we revived an oral formulation of pure As(2)O(3) in 1998 for the treatment of acute promyelocytic leukemia (APL). We were the first to produ...
Autores principales: | Kumana, Cyrus R., Mak, Raymond, Kwong, Yok-Lam, Gill, Harinder |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7418518/ https://www.ncbi.nlm.nih.gov/pubmed/32850403 http://dx.doi.org/10.3389/fonc.2020.01294 |
Ejemplares similares
-
Oral arsenic trioxide for treating acute promyelocytic leukaemia: Implications for its worldwide epidemiology and beyond
por: Kumana, Cyrus R., et al.
Publicado: (2022) -
The Development and Clinical Applications of Oral Arsenic Trioxide for Acute Promyelocytic Leukaemia and Other Diseases
por: Chin, Lynn, et al.
Publicado: (2022) -
Feasibility of oral arsenic trioxide treatment for acute promyelocytic leukemia during hemodialysis
por: Au, Wing-Yan, et al.
Publicado: (2012) -
Takotsubo Syndrome: From Bench to Bedside and Bedside to Bench
por: Pelliccia, Francesco, et al.
Publicado: (2022) -
Bench and Bedside
por: Schmidt, Christian
Publicado: (2002)